» Articles » PMID: 24070090

Oxidative Stress Elicits Platelet/leukocyte Inflammatory Interactions Via HMGB1: a Candidate for Microvessel Injury in Sytemic Sclerosis

Overview
Specialty Endocrinology
Date 2013 Sep 28
PMID 24070090
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: An abnormal generation of reactive oxygen species (ROS) is thought to contribute to systemic sclerosis (SSc), fostering autoimmunity, fibrosis, and vascular inflammation. The function of the prototypic damage-associated molecular pattern, high mobility group box 1 (HMGB1), depends on its redox status. Here we investigate whether oxidative stress regulates the cross-talk between leukocytes and platelets via HMGB1, thus contributing to vessel inflammation in SSc.

Results: The oxidation of HMGB1 amplified its ability to activate neutrophils, as detected assessing the redistribution of primary granule molecules and the transactivation of the β2 integrin chain CD18. Activated platelets are a source of bioactive HMGB1 and via P-selectin stimulated neutrophils to generate ROS. Oxidized extracellular HMGB1, soluble or associated to platelet membrane or to platelet-derived microparticles (PDμPs), further increased leukocyte activation. Leukocyte activation abated in the presence of inhibitors of HMGB1 or of catalase, which catalyzes the dismutation of hydrogen peroxide into water and molecular oxygen. The redistribution of the content of primary granules and the transactivation of β2 integrins characterized blood leukocytes of SSc patients and membrane HMGB1 was significantly higher in patients with pulmonary hypertension or with diffuse SSc. HMGB1(+) microparticles (μPs) purified from SSc patients, but not HMGB1(-) μPs purified from control subjects, activated in vitro healthy neutrophils, and HMGB1 inhibitors reversed the effects of μPs.

Innovation And Conclusion: ROS dramatically increase the ability of extracellular HMGB1 to activate blood leukocytes. This event might contribute to maintain the microvascular injury of patients with SSc.

Citing Articles

The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases.

Zeng L, Xiang W, Xiao W, Wu Y, Sun L MedComm (2020). 2025; 6(3):e70101.

PMID: 40060194 PMC: 11885892. DOI: 10.1002/mco2.70101.


HMGB1: A New Target for Ischemic Stroke and Hemorrhagic Transformation.

Li J, Wang Z, Li J, Zhao H, Ma Q Transl Stroke Res. 2024; .

PMID: 38740617 DOI: 10.1007/s12975-024-01258-5.


Application of Platelet-Rich Plasma as a Stem Cell Treatment - an Attempt to Clarify a Common Public Misconception.

Fareez I, Liew F, Widera D, Mayeen N, Mawya J, Abu Kasim N Curr Mol Med. 2023; 24(6):689-701.

PMID: 37171013 DOI: 10.2174/1566524023666230511152646.


Reappraisal of oxidized HMGB1 as a mediator and biomarker.

Pirnie R, Gillespie K, Mesaros C, Blair I Future Sci OA. 2023; 8(10):FSO828.

PMID: 36874369 PMC: 9979160. DOI: 10.2144/fsoa-2022-0052.


The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.

Kim S, Park H, Lee S Int J Mol Sci. 2022; 23(24).

PMID: 36555792 PMC: 9853331. DOI: 10.3390/ijms232416154.